We are live on
!
Find out more
SC
Stempoint Capital Portfolio holdings
AUM
$522M
1-Year Est. Return
281.95%
This Fund
S&P 500
This Quarter
Est. Return
+25.39%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$375M
AUM Growth
–
Cap. Flow
+$315M
Cap. Flow
% of AUM
83.93%
Top 10 Holdings %
Top 10 Hldgs %
39.49%
Holding
67
New
67
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roivant Sciences
ROIV
|
+$21.1M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$16.8M |
| 3 |
ACLX
Arcellx
ACLX
|
+$14.1M |
| 4 |
Immunovant
IMVT
|
+$11.8M |
| 5 |
MRUS
Merus
MRUS
|
+$11.7M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KALV
26
DELISTED
KalVista Pharmaceuticals
KALV
| $5.18M | 1.38% |
+423,174
| New | +$3.85M |
|
27
Biohaven
BHVN
$2.16B
| $4.77M | 1.27% |
+111,354
| New | +$3.46M |
|
|
SAGE
28
DELISTED
Sage Therapeutics
SAGE
| $4.73M | 1.26% |
+218,319
| New | +$4.33M |
|
29
Madrigal Pharmaceuticals
MDGL
$12.6B
| $4.73M | 1.26% |
+20,444
| New | +$3.58M |
|
30
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $4.72M | 1.26% |
+9,921
| New | +$4.42M |
|
31
ANI Pharmaceuticals
ANIP
$1.77B
| $4.71M | 1.26% |
+85,382
| New | +$4.7M |
|
|
ALPN
32
DELISTED
Alpine Immune Sciences Inc
ALPN
| $4.69M | 1.25% |
+246,178
| New | +$3.42M |
|
|
ETNB
33
DELISTED
89bio
ETNB
| $4.56M | 1.22% |
+408,257
| New | +$3.75M |
|
|
SLRN
34
DELISTED
ACELYRIN
SLRN
| $4.38M | 1.17% |
+587,373
| New | +$5.01M |
|
|
CBAY
35
DELISTED
Cymabay Therapeutics
CBAY
| $4.3M | 1.15% |
+182,258
| New | +$3.25M |
|
36
Olema Pharmaceuticals
OLMA
$1.02B
| $3.95M | 1.05% |
+281,287
| New | +$3.78M |
|
37
Larimar Therapeutics
LRMR
$416M
| $3.56M | 0.95% |
+783,172
| New | +$2.64M |
|
|
SCPH
38
DELISTED
scPharmaceuticals
SCPH
| $3.56M | 0.95% |
+567,211
| New | +$3.25M |
|
39
Fate Therapeutics
FATE
$281M
| $3.36M | 0.9% |
+898,196
| New | +$2.12M |
|
40
Kiniksa Pharmaceuticals
KNSA
$4.83B
| $3.21M | 0.86% |
+183,102
| New | +$3.01M |
|
|
APLT
41
DELISTED
Applied Therapeutics
APLT
| $3.04M | 0.81% |
+907,152
| New | +$2.26M |
|
42
Neurocrine Biosciences
NBIX
$17.7B
| $2.96M | 0.79% |
+22,500
| New | +$2.59M |
|
43
CALL
Jasper Therapeutics
JSPR
$22.9M
| $2.92M | 0.78% |
+370,711
| New | +$2.49M |
|
|
AUTL
44
Autolus Therapeutics
AUTL
$386M
| $2.91M | 0.78% |
+451,375
| New | +$1.72M |
|
45
Annexon
ANNX
$855M
| $2.76M | 0.74% |
+607,100
| New | +$1.5M |
|
|
MOR
46
CALL
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $2.75M | 0.73% |
+277,485
| New | +$2.04M |
|
47
Fulcrum Therapeutics
FULC
$248M
| $2.54M | 0.68% |
+376,573
| New | +$1.67M |
|
48
EyePoint Inc
EYPT
$1.02B
| $2.21M | 0.59% |
+95,732
| New | +$1.07M |
|
49
AC Immune
ACIU
$227M
| $2.17M | 0.58% |
+434,588
| New | +$1.4M |
|
50
Cytokinetics
CYTK
$11B
| $2.01M | 0.54% |
+24,111
| New | +$873K |
|
Similar funds
JE
GS
LT
SCM
ETS
CM
SW
SRFM
Stempoint Capital's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Stempoint Capital, which disclosed 67 positions worth $375M. Its ten largest holdings account for 39% of the portfolio.
Its largest position is Roivant Sciences: 2,169,116 shares worth $24.4M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets.
- Stempoint Capital's largest Q4 2023 buy was Roivant Sciences: 2,169,116 shares worth $24.4M.
- Stempoint Capital's ten largest holdings make up 39% of its $375M portfolio in Q4 2023.
- Stempoint Capital disclosed 67 positions in Q4 2023, its first 13F filing on record.
Based on Stempoint Capital's 13F filing for Q4 2023, filed 13 Feb 2024.